Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Solesence (SLSN) Shares Outstanding (Weighted Average) (2016 - 2025)

Solesence's Shares Outstanding (Weighted Average) history spans 16 years, with the latest figure at $70.3 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 12.82% year-over-year to $70.3 million; the TTM value through Dec 2025 reached $70.3 million, up 12.82%, while the annual FY2025 figure was $70.3 million, 12.82% up from the prior year.
  • Shares Outstanding (Weighted Average) reached $70.3 million in Q4 2025 per SLSN's latest filing, roughly flat from $70.3 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $70.3 million in Q4 2025 to a low of $38.2 million in Q1 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $54.4 million, with a median of $49.5 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding (Weighted Average): increased 0.22% in 2021, then soared 41.07% in 2024.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $45.0 million in 2021, then increased by 9.1% to $49.1 million in 2022, then rose by 0.89% to $49.6 million in 2023, then rose by 25.82% to $62.4 million in 2024, then increased by 12.82% to $70.3 million in 2025.
  • Per Business Quant, the three most recent readings for SLSN's Shares Outstanding (Weighted Average) are $70.3 million (Q4 2025), $70.3 million (Q3 2025), and $70.2 million (Q2 2025).